A trial on Plasma-based therapeutic in patients with mild to moderate Alzheimer's Disease (AD)

Trial Profile

A trial on Plasma-based therapeutic in patients with mild to moderate Alzheimer's Disease (AD)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Plasma-based-therapeutic-Alkahest/Grifols (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms PLASMA
  • Sponsors Alkahest
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 01 Nov 2017 Results presnted in an Alkahest Media Release.
    • 01 Nov 2017 According to an Alkahest media release, Nine subjects were enrolled randomized and treated under the double-blind crossover protocol, and an additional nine subjects were enrolled and treated under an open-label amendment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top